ID   41M
AC   CVCL_4993
SY   41-M; OAW41M; 041M; 41 M
DR   BTO; BTO:0003998
DR   BioSample; SAMN03151866
DR   ChEMBL-Cells; CHEMBL3307631
DR   ChEMBL-Targets; CHEMBL614511
DR   ECACC; 93061002
DR   GEO; GSM313659
DR   GEO; GSM851922
DR   Progenetix; CVCL_4993
DR   PubChem_Cell_line; CVCL_4993
DR   Wikidata; Q54602996
RX   PubMed=1423261;
RX   PubMed=1617660;
RX   PubMed=1892748;
RX   PubMed=2653399;
RX   PubMed=8795574;
RX   PubMed=15677628;
RX   PubMed=20143388;
RX   PubMed=22710073;
RX   PubMed=23415752;
CC   Problematic cell line: Contaminated. Shown to be a OAW28 derivative (PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00110.
CC   Population: Caucasian.
CC   Doubling time: 27 hours (PubMed=2653399).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Misspelling: M41; GEO=GSM851922.
CC   Discontinued: ECACC; 93061002; probable.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=22710073
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 12,14
ST   D19S433: 13
ST   D21S11: 29
ST   D2S1338: 20,23
ST   D3S1358: 14,18
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 11,15
ST   FGA: 21,24
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1614 ! OAW28
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 29
RX   PubMed=1423261;
RA   Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.;
RT   "Comparison of cellular accumulation and cytotoxicity of cisplatin
RT   with that of tetraplatin and
RT   amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human
RT   ovarian carcinoma cell lines.";
RL   Cancer Res. 52:6188-6193(1992).
RX   PubMed=1617660;
RA   Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A.,
RA   Harrap K.R.;
RT   "Mechanism-related circumvention of acquired
RT   cis-diamminedichloroplatinum(II) resistance using two pairs of human
RT   ovarian carcinoma cell lines by ammine/amine platinum(IV)
RT   dicarboxylates.";
RL   Cancer Res. 52:3857-3864(1992).
RX   PubMed=1892748; DOI=10.1038/bjc.1991.279;
RA   Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.;
RT   "The relationships between glutathione, glutathione-S-transferase and
RT   cytotoxicity of platinum drugs and melphalan in eight human ovarian
RT   carcinoma cell lines.";
RL   Br. J. Cancer 64:215-220(1991).
RX   PubMed=2653399; DOI=10.1038/bjc.1989.108;
RA   Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P.,
RA   Harrap K.R.;
RT   "Biological properties of ten human ovarian carcinoma cell lines:
RT   calibration in vitro against four platinum complexes.";
RL   Br. J. Cancer 59:527-534(1989).
RX   PubMed=8795574; DOI=10.1038/bjc.1996.428;
RA   Wilson A.P., Dent M., Pejovic T., Hubbold L., Radford H.;
RT   "Characterisation of seven human ovarian tumour cell lines.";
RL   Br. J. Cancer 74:722-727(1996).
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).